Form 4: REGENXBIO Director Kenneth T. Mills Exercises Stock Options
SEC Form 4
Director Kenneth T. Mills exercised stock options to acquire 30,752 shares of REGENXBIO Inc. common stock at a price of $3.76 on March 27, 2025.
Summary
- On March 27, 2025, Kenneth T. Mills, a director of REGENXBIO Inc., exercised stock options.
- This transaction involved the acquisition of 30,752 shares of common stock at a price of $3.76 per share.
- Following the transaction, Mills directly owns 475,103 shares of REGENXBIO Inc. common stock.
- Mills also owns 20,602 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 05/19/2016 | 25% of the options vested. |
| 03/27/2025 | Date of transaction: Kenneth T. Mills exercised stock options. |
| 03/31/2025 | Date of signature on the Form 4 filing. |
| 05/19/2025 | Expiration date of the exercised options. |
Keywords
REGENXBIO, Director, Stock Options, Form 4, RGNX, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.